The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.
 
Kathryn Cecilia Arbour
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Hira Rizvi
No Relationships to Disclose
 
Andrew J. Plodkowski
No Relationships to Disclose
 
Darragh Halpenny
Honoraria - OncLive (I)
Consulting or Advisory Role - GlaxoSmithKline (I); Tesaro (I)
Research Funding - AstraZeneca (I); Syndax (I)
Travel, Accommodations, Expenses - AstraZeneca (I)
 
Matthew David Hellmann
Stock and Other Ownership Interests - Immunai; Shattuck Labs
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca/MedImmune; Blueprint Medicines; Bristol-Myers Squibb; Genentech; Immunai; Merck; Mirati Therapeutics; Nektar; Shattuck Labs; Syndax
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - A patent has been filed by Memorial Sloan Kettering (PCT/US2015/062208) for the use of tumor mutation burden for prediction of immunotherapy efficacy, and which is licensed to Personal Genome Diagnostics. (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb
 
Glenn Heller
Research Funding - Janssen Diagnostics
 
Andrea Knezevic
No Relationships to Disclose
 
Helena Alexandra Yu
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Lilly
Other Relationship - Astellas Pharma
 
Marc Ladanyi
Honoraria - Merck (I)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck (I); NCCN/AstraZeneca; Takeda
Research Funding - Helsinn Therapeutics; Loxo (Inst)
 
Mark G. Kris
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Pfizer; Regeneron
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Pfizer
Other Relationship - Memorial Sloan-Kettering Cancer Center
 
Maria E. Arcila
Honoraria - Biocartis; Invivoscribe
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; Invivoscribe; Raindance Technologies
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Amgen; Ascentage Pharma; AstraZeneca; Bicycle Therapeutics; Bridge Medicines; Celgene; Daiichi Sankyo; Genentech/Roche; Harpoon Therapeutics; Ipsen; Loxo; PharmaMar; PharmaMar
Research Funding - Abbvie/Stemcentrx (Inst); Daiichi Sankyo (Inst); Merck (Inst); Viralytics (Inst)
 
Piro Lito
Research Funding - Mirati Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - I am listed as an inventor on a patent application filed by MSKCC that describes an approach to treat BRAF mutant cancers. (Inst); I am listed as an inventor on a patent application filed by MSKCC that describes an approach to treat KRAS mutant cancers. (Inst)
 
Gregory J. Riely
Research Funding - GlaxoSmithKline (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
Other Relationship - Pfizer; Roche/Genentech; Takeda